newsfilter
← Latest News
GlobeNewswire·

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

  • Fractyl Health appointed Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy.
  • Zumdahl previously served as Vice President of Global Health Economics, Market Access, and Government Affairs at Inari Medical before its 2025 acquisition by Stryker for approximately $4.9 billion.
  • Prior to Inari, Zumdahl was President of Commercial Access Partners and spent nearly a decade at Novo Nordisk working on GLP-1 therapies.
  • The appointment positions Fractyl for the anticipated REMAIN-1 Pivotal Cohort topline readout in early Q4 2026.
  • Fractyl plans to submit a potential De Novo marketing application for Revita® in late Q4 2026.
  • Revita is a one-time, minimally invasive endoscopic procedure designed for weight maintenance in individuals with obesity who discontinue GLP-1 therapies.
  • Revita holds Breakthrough Device designation from the FDA for this indication and is CE marked in the EU and UK.
  • Fractyl Health is headquartered in Burlington, Massachusetts, and is also advancing its gene therapy platform Rejuva with candidate RJVA-001 in first-in-human studies.